Swiss pharmaceutical company Novartis has filed a lawsuit against President Joe Biden's administration over a disagreement regarding the 340B Drug Discount Program. The company claims that the U.S. Health Resources and Services Administration interpreted a federal law wrongly, preventing Novartis from changing payment terms for participating hospitals. This move by Novartis could have significant repercussions on the negotiation process for the company's popular heart drug, Entresto, and its pricing under Medicare. Stay updated on market-moving news with TheFly and check out top-performing stocks on TipRanks.
Novartis Sues Biden Administration Over 340B Drug Discount Program
Swiss pharmaceutical giant Novartis has filed a lawsuit against the Biden administration over a disagreement regarding the 340B Drug Discount Program. The company claims that the U.S. Health Resources and Services Administration (HRSA) interpreted a federal law wrongly, preventing Novartis from changing payment terms for participating hospitals.
The 340B Drug Discount Program is a federal program that was established in 1992 to provide discounted prescription drugs to low-income and uninsured patients. Hospitals that participate in the program are required to pass along the discounts they receive from drug manufacturers to patients.
Novartis argues that the HRSA has misinterpreted the 340B law by requiring drug manufacturers to provide discounts to hospitals regardless of whether the drugs are actually used to treat low-income or uninsured patients. The company says that this interpretation of the law has led to "significant overpayments" to hospitals and that it has been forced to subsidize the program with its own profits.
The lawsuit could have significant repercussions on the negotiation process for Novartis's popular heart drug, Entresto. The drug is currently covered under Medicare Part D, and Novartis is seeking to change the payment terms for Entresto in order to increase its profits. The lawsuit could delay or prevent Novartis from making these changes, which could impact the price of Entresto for Medicare beneficiaries.
Background
The 340B Drug Discount Program was created as part of the Omnibus Budget Reconciliation Act of 1990. The program was originally designed to help hospitals that serve a disproportionate share of low-income and uninsured patients. The program has since been expanded to include a wider range of hospitals, including many that do not serve a disproportionate share of low-income and uninsured patients.
In 2010, the Affordable Care Act made significant changes to the 340B program. The changes included adding new eligibility requirements for hospitals and increasing the discounts that drug manufacturers are required to provide.
Top 5 FAQs
1. What is the 340B Drug Discount Program?
The 340B Drug Discount Program is a federal program that requires drug manufacturers to provide discounts to hospitals that serve a disproportionate share of low-income and uninsured patients. The program is designed to help these hospitals provide affordable prescription drugs to their patients.
2. What is Novartis's lawsuit about?
Novartis is suing the Biden administration over the HRSA's interpretation of the 340B law. Novartis argues that the HRSA is requiring drug manufacturers to provide discounts to hospitals regardless of whether the drugs are actually used to treat low-income or uninsured patients.
3. What could the lawsuit mean for Novartis?
The lawsuit could delay or prevent Novartis from making changes to the payment terms for its popular heart drug, Entresto. This could impact the price of Entresto for Medicare beneficiaries.
4. What could the lawsuit mean for the 340B program?
The lawsuit could have a significant impact on the 340B program. If Novartis is successful in its lawsuit, it could lead to changes in the way that the program is administered. This could make it more difficult for hospitals to participate in the program or could reduce the discounts that hospitals receive from drug manufacturers.
5. What is the future of the 340B program?
The future of the 340B program is uncertain. The program has been the subject of ongoing debate, with some stakeholders arguing that it is too costly and that it does not effectively target low-income and uninsured patients. However, the program remains popular with hospitals and patient advocates, and it is likely to continue to be a source of controversy in the years to come.
In an effort to reduce reliance on China for key minerals used in advanced technologies, India is exploring partnership with a rebel group in Myanmar to secure rare earth samples. The Ministry of Mines has directed state-owned and private companies to collect samples from Kachin Independence Army-controlled mines and test them in domestic labs. This move comes in light of China's recent export restrictions on rare earth magnets, causing disruptions in global supply chains.
Oracle chairman Larry Ellison, who hails from the Bronx, has surpassed Tesla CEO Elon Musk as the richest person in the world with a net worth of $405 billion. This jump in wealth was reported by Barron's on Wednesday, putting Ellison ahead of Musk's net worth of $390 billion. This milestone marks a shift in the top spot amongst the world's wealthiest individuals.
The US Producer Price Index fell 0.1% in August, bucking expectations of a rise and indicating a potential slowdown in overall economic growth. The decline was driven by a slump in the cost of services, particularly within wholesalers and retailers. The news has led to a drop in Treasury yields and solidifies expectations of an interest rate cut by the Federal Reserve next week.
The Hilton Kathmandu, once a symbol of Nepal's ambition and modern design, recently fell victim to violent anti-government protests. The hotel, built by the Shanker Group with a significant investment and featuring luxurious amenities and seismic safeguards, opened in 2024 but tragically, went up in flames a year later. The Hilton was not just a hotel, but a cultural statement, embodying Nepalese heritage and offering breathtaking views of the Langtang range.
In a shocking incident, a brand-new Mahindra Thar crashed through a glass wall and landed on the road below in Delhi's Preet Vihar. The SUV had just been purchased by a couple who were inside the vehicle at the time with a showroom salesman. Fortunately, no one was seriously injured in the accident. The incident, captured on video, has gone viral on social media. Police are investigating the cause of the incident.
Delhi-based manufacturer Vikas Ecotech has acquired an existing Plasticizer Manufacturing Business, valued at Rs 270 million, in an all-cash deal. With this acquisition, the company aims to enhance its product offering and become debt-free by 2023-24. This move comes after the firm recently paid off Rs 101 crore of its debt to lenders.
The Indian Express has obtained information that the Registrar General of India has requested a budget of Rs 14,618.95 crore for the upcoming Census 2027. This will be the first "digital census" and will include the collection of caste data through dedicated mobile applications. The option for self-enumeration will also be provided to the public. Additionally, Indian refiners have saved approximately $12.6 billion in the past three years through their Russian oil imports, which has caused tensions with the Trump administration.
The Trump administration's latest move has caused major disruptions in the Indian export industry with the imposition of 50% tariffs on Indian goods. Sectors such as apparel, textiles, gems, and jewelry will bear the brunt of the higher tariffs, putting low-skilled jobs in India at risk. India's response has been to extend tariff exemptions on cotton imports, but many are criticizing the government for not taking strong action against the US. Political figures like Saurabh Bhardwaj and Akhilesh Yadav have slammed the BJP-led government for its failed foreign and economic policies which are negatively impacting traders, manufacturers, and workers.
The highly anticipated 2025 model of the popular Suzuki Access 125 has finally been unveiled at the Auto Expo. While it comes in three variants and boasts 5 different colour options, there are complaints about the fluctuating mileage and poor design choices such as fixed mirrors. With tough competition in the two-wheeler market, Suzuki may need to offer attractive deals to customers to stay ahead.
At the Plumbex India exhibition, Minister Hardeep S Puri launched the BHARAT TAP initiative, which aims to improve products and services related to plumbing, water, and sanitation. In his speech, Puri emphasized the importance of sanitation in India's development and praised the success of the Swachh Bharat Mission and AMRUT in achieving 100% toilet coverage in rural areas and significant progress in urban areas. He also announced the launch of AMRUT 2.0, with an outlay of Rs. 2,77,000 crores, to further strengthen water and sanitation services in cities.